IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients
Phase 2
Completed
NCT01009840
| Condition | Multiple Myeloma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| Status | Completed |
|---|
| Enrollment | 30 participants |
|---|
| Interventions | IV busulfan, bortezomib, Autologous Hematopoietic Stem Cell Transplant (HSCT) |
|---|
| Start date | May 1, 2010 |
|---|
| Completion date | Mar 1, 2012 |
|---|
| Results posted | Aug 7, 2014 |
|---|
Summary
Study for the outcome and safety of individualized busulfan dosing with bortezomib for patients preparing for a second stem cell transplant to treat multiple myeloma.
Percentage of Participants With Overall Disease Response at Month 6
6 Months · Percentage of participants
| IV Busulfan | 20.0 Percentage of participants |
|---|
| IV Busulfan | 70.0 Percentage of participants |
|---|
| IV Busulfan | 10.0 Percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.